Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Oct 8;305(11):E1367–E1374. doi: 10.1152/ajpendo.00413.2013

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2013 the American Physiological Society

PMC Copyright notice

Fig. 3. — A: VTA administration of the NMDA receptor antagonist MK-801 (0.05 μg; vehicle, 100 nl of aCSF) does not attenuate the intake-suppressive effect of VTA GLP-1R activation by Ex-4 (0.05 μg; vehicle, 100 nl of aCSF). B: VTA MK-801 does not attenuate VTA Ex-4-induced reductions in meal size. C: no effects on meal frequency were observed (all P > 0.05). *Main effect of Ex-4 (P < 0.05); main effect of MK-801 (P < 0.05); #statistically significant interaction between MK-801 and Ex-4. Within time bin, bars with different letters are significantly different from each other (P < 0.05). All data are shown as means ± SE.

Inline graphic — A: VTA administration of the NMDA receptor antagonist MK-801 (0.05 μg; vehicle, 100 nl of aCSF) does not attenuate the intake-suppressive effect of VTA GLP-1R activation by Ex-4 (0.05 μg; vehicle, 100 nl of aCSF). B: VTA MK-801 does not attenuate VTA Ex-4-induced reductions in meal size. C: no effects on meal frequency were observed (all P > 0.05). *Main effect of Ex-4 (P < 0.05); main effect of MK-801 (P < 0.05); #statistically significant interaction between MK-801 and Ex-4. Within time bin, bars with different letters are significantly different from each other (P < 0.05). All data are shown as means ± SE.